EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center

Artur Bandura iD, Monika Mierzejewska iD, Wojciech Cytawa, Rafał Dziadziuszko iD

Cancers · 09.06.2026 · 18 (12) · 1880

DOI: 10.3390/cancers18121880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 09.06.2026. Verfasst von Artur Bandura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80-210 Gdańsk, Poland. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oligometastatic non-small cell lung cancer (OMD NSCLC) represents a distinct clinical state with limited metastatic spread, where local ablative therapies (LAT) combined with systemic treatment may improve outcomes. Accurate staging and prognostic assessment are critical, with 18F-FDG PET/CT emerging as a valuable tool for detecting metabolically active tumor burden.

Results

We retrospectively analyzed 38 patients with synchronous OMD NSCLC who received radiotherapy. All patients underwent 18F-PET/CT and brain imaging for staging. Semi-quantitative 18F-PET/CT parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of primary tumor and metastatic lesions, were measured and associated with progression-free survival (PFS) and overall survival (OS) using Cox proportional hazard models. The median PFS and OS were 8.28 and 21.62 months, respectively. Higher MTV and TLG values of metastases were significantly associated with shorter PFS and OS (p < 0.01). In multivariable analysis, TLG of metastases above the median remained an independent predictor of worse PFS (HR = 2.78, p = 0.031) and OS (HR = 3.12, p = 0.024), alongside clinical factors such as ECOG performance status 2 and having multiple metastases. The metabolic parameters of the primary tumor did not predict survival outcomes. Conclusions:18F-PET/CT-derived metabolic parameters, particularly the TLG of metastatic lesions, may provide significant prognostic information in oligometastatic NSCLC beyond clinical variables. These findings may support the integration of 18F-PET/CT metrics for future trials involving patients treated with LAT in oligometastatic NSCLC.

Schlagwörter

Stichwörter der Autor:innen

18F-fluorodeoxyglucose positron emission tomography/computed tomographymetabolic tumor volumenon-small cell lung canceroligometastaticradiotherapytotal lesion glycolysis

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
  • Department of Nuclear Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland.

ORCID-Profile: Artur Bandura, Monika Mierzejewska, Rafał Dziadziuszko

Zitieren

APA

Bandura, A., Mierzejewska, M., Cytawa, W., & Dziadziuszko, R. (2026). Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center. Cancers, 18(12), 1880. https://doi.org/10.3390/cancers18121880

Vancouver

Bandura A, Mierzejewska M, Cytawa W, Dziadziuszko R. Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center. Cancers. 2026;18(12):1880. doi:10.3390/cancers18121880

BibTeX
@article{Bandura2026,
  author = {Bandura, Artur and Mierzejewska, Monika and Cytawa, Wojciech and Dziadziuszko, Rafał},
  title = {Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1880},
  doi = {10.3390/cancers18121880}
}
Kostenlos starten →